Cancer Immunology and Immunotherapy

Cellular immunity depends mainly on the ability of DCs to take up and process antigens in the peripheral blood and tissues. In cancer, this process is not robust enough to produce meaningful antitumor responses.  Monoclonal antibodies are proteins produced by B-cells that bind to a specific antigen. They are currently one of the most successful forms of cancer immunotherapy. We should differentiate between monoclonal antibody-based cancer therapy and monoclonal antibody-based immunotherapy of cancer. This can be illustrated by the differences in their mechanisms of action. Anti-neoplastic agents such as bevacizumab block ligand–receptor interaction, thereby affecting growth or survival pathways, where monoclonal antibodies such as rituximab cause antibody-dependent cellular cytotoxicity and complement-mediated cytotoxicity. Antibodies are also being used to enhance the strength of the immune response. As mentioned earlier, activated T-cells and tumour cells express CTLA4 receptors as an immune-suppressive mechanism to protect against autoimmunity and to escape elimination. Antagonism of these receptors has shown antitumor benefit. For example, ipilimumab inhibits the receptor CTLA4, permitting persistent T-cell activation. Similarly, PD1 is expressed on activated T- and B-cells and when bound to by PD1 ligand they become deactivated (10-12). Tumour cells tend to overexpress PD1 ligands, allowing them to deactivate this response.

  • Antibody-based immunotherapy of cancer
  • Cytokine-based immunotherapy of cancer
  • Anti CTLA4
  • Hodgkin's lymphoma

 

Related:

Allergy and Clinical Immunology Conference | Allergen Conference | Allergic Conference | Anaphylactic shock Conference | Anaphylaxis Conference | Tolerate | Sensitivity | Intolerant Conference | Hypoallergenic Conference | Hypersensitive Conference | Innate Immunity | Immunogenetics Conference | Immunologic Neuropathies | Immunodiagnostics Conference | Immune Tolerance Conference.

 

 

Related Societies and Associations: American Academy of Allergy, Asthma and Immunology (AAAAI), American Board of Allergy and Immunology (ABAI), Asociacion de Alergia, Asma e Inmunologia "Buenos Aires" (AAIBA), Association of Universities and Colleges of Canada (AUCC), Canadian Society of Allergy and Clinical Immunology (CSACI), Canadian Society for Immunology (CSI), Macedonian Society for Basic, Clinical Immunology & Allergology (MSBCIA), Norwegian Society for Immunology (NSI), Australasian Society for Immunology (ASI), Association of Medical Laboratory Immunologists (AMLI), International Cytokine Society (ICS), Society for Leukocyte Biology (SLB), Society for Immunology and Immunopathology (SIIP), Federation Of Clinical Immunology Societies (FOCIS), European Academy of Allergology and Clinical Immunology (EAACI), European Society for Analytical Cellular Pathology (ESACP).

 

    Related Conference of Cancer Immunology and Immunotherapy

    March 18-19, 2021

    3rd World Conference on Vaccine and Immunology

    Dubai, UAE
    April 05-05, 2021

    Tumor & Cancer Immunology and Pediatric-Oncology

    Toronto, Canada
    May 03-04, 2021

    International Online Conference on Immunology

    New York, USA
    June 23-24, 2021

    34th World Congress on Vaccines and Immunization

    Osaka, Australia
    October 12-13, 2021

    International Conference on Vaccine and Vaccine research

    Manila, Philippines
    October 14-15, 2021

    13th Annual Conference on Cinical Immunology

    Cape Town, Australia
    October 14-15, 2021

    11th International Conference on Bacteriology and Infectious Diseases

    Cape Town, South Africa

    Cancer Immunology and Immunotherapy Conference Speakers

    Recommended Sessions

    Related Journals

    Are you interested in